Collaborations & Alliances
Related Searches:
Filter by:
706 - 720 of 1104 results
September 1, 2009
Selexis SA and NKT Therapeutics (NKTT) have entered into a research services agreement under which Selexis will screen antibody variants and generate high performance CHO-based production cell lines using their INTEGRA-D2M platform.
Read More »
August 28, 2009
Biotie has reached a milestone in its collaboration with Wyeth for the development of PDE10 (phosphodiesterase 10) inhibitors for schizophrenia, triggering a $1.0 million milestone payment to Biotie.
Read More »
August 25, 2009
Wyeth has agreed to take on all of Karo Bio’s future R&D activities under the companies’ drug discovery collaboration, beginning September 1, 2009.
Read More »
August 24, 2009
Santhera Pharmaceuticals and Biovail Corp. have signed a license agreement for Santhera's JP-1730/fipamezole, granting Biovail U.S. and Canadian rights to develop and commercialize the drug for the treatment of dyskinesia in Parkinson's Disease.
Read More »
August 20, 2009
ChemDiv, Inc. and Lilly have expanded their drug discovery collaboration through 2010.
Read More »
August 13, 2009
Phase Forward and SGS have extended their multi-year, multi-million dollar partnership
Read More »
August 12, 2009
Forest Labs and AZ will co-develop and commercialize ceftaroline in all markets outside the U.S., Canada and Japan
Read More »
August 10, 2009
Nycomed and Forest Laboratories have entered into a collaboration and distribution agreement for Daxas in the U.S.
Read More »
August 3, 2009
Cherokee Pharmaceuticals has signed a new five-and-a-half-year commercial supply agreement with DuPont Applied BioSciences
Read More »
July 28, 2009
Amgen and GlaxoSmithKline entered into a collaboration under which the companies will share commercialization of Amgen's monoclonal antibody denosumab for postmenopausal osteoporosis (PMO) in Europe, Australia, New Zealand and Mexico, once approved in the
Read More »
July 17, 2009
Novartis has extended its RNAi therapeutics collaboration with Alnylam Pharmaceuticals for a fifth and final year, through October 2010.
Read More »
July 17, 2009
Gilead Sciences and Tibotec Pharmaceuticals, a unit of Johnson & Johnson, have entered an agreement to develop and commercialize a new fixed-dose combination of Truvada and TMC278 (rilpivirine).
Read More »
July 15, 2009
Sartorius Stedim Biotech (SSB) and SAFC Biosciences have signed a global partnership agreement aimed at providing more comprehensive solutions to biopharmaceutical manufacturers.
Read More »
July 13, 2009
InNexus and Genhelix plan a strategic collaboration in antibody development.
Read More »
July 10, 2009
AstraZeneca has terminated its license agreement with MAP Pharmaceuticals, Inc. related to the company's Unit Dose Budesonide (UDB) product candidate.
Read More »
706 - 720 of 1104 results
